The immunizer was developed by the pharmaceutical company Moderna, in the United Kingdom, and is called bivalent.
The United Kingdom on Monday became the first country to approve an updated version of the vaccine against COVID-19. The immunizer, developed by Moderna pharmaceutical, is bivalent, that is, it has a formulation that involves both the original strain of Sars-CoV-2, discovered in China in 2019, and the Subvariant BA.1 of Ômicronidentified in 2021 in South Africa.
The announcement was made by the UK Medicines and Healthcare Products Regulatory Agency (MHRA). Now, the British Joint Committee on Vaccination and Immunization (JCVI) will decide whether the new vaccine will be incorporated into the vaccination campaign before the next winter, in December in the Northern Hemisphere.
Read more: see what the vaccination against COVID will be like in children aged 3 to 5 years
According to June Raine, chief executive of the MHRA, the first generation of vaccines “continue to provide important protection against disease and to save lives”. “What this bivalent vaccine gives us is a sharp tool in our armor to help us protect against the COVID-19 as the virus continues to evolve,” it said in a statement.
Protection against other subvariants of Ômicron
The rapid evolution of Ômicron, with the emergence of its subvariants (BA.1 to BA.5), has raised concerns on the part of the authorities regarding the efficacy of immunizers developed with the first detected version. Currently, the predominant sublines are BA.4 and BA.5.
According to Moderna, the approved vaccine now also offers protection for these two emerging subvariants. According to phase 2 clinical trials, released by the pharmaceutical company, the immunizer induced an eight-fold increase in the production of antibodies against Omicron BA.1 when applied as a booster. In relation to BA.4 and BA.5, the increase was 6.3 times.
For Professor Munir Pirmohamed, Chair of the MHRA Human Medicines Commission, the new bivalent vaccine “represents the next step in the development of immunizations to fight the virus, with its ability to lead to a broader immune response than the original vaccine.” .
Know more: COVID vaccine guarantees greater protection for those already infected
In addition to the United Kingdom, the application for approval was also made by Moderna in Canada, the European Union and Australia. Brazil does not use vaccines from the pharmaceutical company in its vaccine campaign against COVID-19 and, therefore, should not receive the request.
Content for educational purposes only. Consult a Doctor.
The translator user relied on the following source:
Minha Vida Website – REF99827
Disclaimer – (English version>) This content has been prepared based on information from research, additional publications, or the translation/verification work of a volunteer editor of this web council. This is a non-profit service. It is strongly recommended that all details and information published be carefully verified. We never allow medication recommendations, medication package inserts or any medication guidance. We never allow partisan politics as information.
Isenção de responsabilidade – (versão em português): Este conteúdo foi preparado com base em informações de pesquisas, publicações adicionais ou no trabalho de tradução/verificação de um editor voluntário deste conselho web. Este é um serviço sem fins lucrativos. É altamente recomendável que todos os detalhes e informações publicadas sejam verificadas cuidadosamente. Nunca permitimos recomendações de medicamentos, bulas ou qualquer orientação sobre medicamentos. Nunca permitimos a política partidária como base para checagem. Para mais informações, leia nossos termos.